AstraZeneca had a strong finish to the year and its shares have achieved an all-time high at 194.18 USD. They completed listing in New York, balancing both the US and China markets. This is due to a strong demand for its cancer drugs and their reiteration of a lofty $80 billion 2030 view. Significant investments have been made in AstraZeneca, such as Cookson Peirce & Co. Inc. investing $1.05 Million and Wesbanco Bank Inc. purchasing shares. It was asserted that AstraZeneca is one of the best pharma stocks to invest in. AstraZeneca’s Q4 2025 revenue grew by 8% which pushed their stock price. Their stocks have started in the New York Stock Exchange, being praised for the portfolio and pipeline supporting solid long-term growth. Furthermore, AstraZeneca’s earnings have shown momentum across its growth franchises.
AstraZeneca Stocks News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 09:08:22 GMT -
Rating 8
- Innovation 2
- Rumor -6
